Related Experiment Video
Updated: Jun 13, 2025

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access
Jesús Garcia-Foncillas1, Arnaud Bayle2,3, Dirk Arnold4
1University Cancer Institute & The Department of Oncology, University Hospital Fundacion Jimenez Diaz, Autonomous University, Madrid, Spain.
Abstract:
The advent of advanced biomolecular technologies for detecting molecular and genomic signatures of individual tumors has transformed oncology care, introducing proven methodologies that can inform treatment with matched targeted therapies and predict response at the individual patient level. However, access to these technologies has been hampered by multiple barriers, most notably price and obtainability. Other barriers include lack of knowledge of available technologies, concerns about value, and outdated infrastructures that impede critical operations within the clinic or laboratory. Accessibility barriers to advanced biomolecular testing are critically important to patient care, as new technological advances in molecular medicine continue to outpace the implementation of solutions. Given the proven evidence for improved patient outcomes with precision oncology medicines, it is imperative to understand the value afforded by these technologies. The purpose of this narrative review is to describe existing and emerging barriers to access and present a "roadmap to access" that will facilitate the urgently needed discussions to identify solutions for improving access. Implementation of these solutions will raise awareness of available technologies and treatments and their prognostic significance, improve evidence collection for demonstration of value, and fortify clinical and laboratory infrastructure and operations.
Insights
Advanced biomolecular testing improves cancer care but faces access barriers like cost and knowledge gaps. Addressing these challenges is crucial for equitable precision oncology and better patient outcomes.
Area of Science:
- Biomolecular technologies
- Genomic signatures
- Precision oncology
Background:
- Advanced biomolecular technologies transform oncology by enabling personalized treatments based on tumor molecular and genomic signatures.
- Despite proven benefits for patient outcomes, access to these precision oncology tools is limited by significant barriers.
Purpose of the Study:
- To identify and describe existing and emerging barriers hindering access to advanced biomolecular testing.
- To propose a "roadmap to access" to guide discussions and solutions for improving accessibility.
Main Methods:
- This narrative review synthesizes information on barriers to advanced biomolecular testing.
- It outlines strategies for improving access and implementation.
Main Results:
- Key barriers include high cost, limited availability, lack of knowledge, value concerns, and inadequate clinical/laboratory infrastructure.
- A roadmap is proposed to address these issues.
Conclusions:
- Overcoming access barriers is essential for realizing the full potential of precision oncology.
- Implementing solutions will enhance awareness, demonstrate value, and strengthen healthcare infrastructure.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...